Currently, food industries use supplements fromAloe veraas highly concentrated powders (starting products), which are added to the final product at a concentration of 1x, meaning 10 g/L for decolourized and spray-dried whole leaf powder (WLP) or 5 g/L for decolourized and spray-dried inner leaf powder (ILG) and also for nondecolourized and belt-dried inner leaf powder (ILF). Flavonoids, tannins, or saponins could not be detected for any starting product at this concentration and their total phenol concentration of 68–112 μM gallate-eq. was much lower than in fresh extract; however, their antioxidant capacity of 90–123 μM ascorbate-eq. for DPPH was similar to the fresh extract. Starting products, dissolved at 1x, had an aloin concentration of 0.04 to 0.07 ppm, a concentration much lower than the industry standard of 10 ppm for foodstuff. While decolourized starting products (i.e., treated with activated carbon) exhibited low cytotoxicity on HeLa cells (CC50= 15 g/L ILG or 50 g/L WLP), ILF at CC50= 1–5 g/L exhibited cytotoxic effects, that is, at concentrations even below the recommended for human consumption. Probable causes for the cytotoxicity of ILF are the exposure to high temperatures (70–85°C) combined with a high fibre content.
Currently, antimicrobial resistance (AMR) is a serious health problem in the world, mainly because of the rapid spread of multidrug-resistant (MDR) bacteria. These include bacteria that produce β-lactamases, which confer resistance to β-lactams, the antibiotics with the most prescriptions in the world. Carbapenems are particularly noteworthy because they are considered the ultimate therapeutic option for MDR bacteria. However, this group of antibiotics can also be hydrolyzed by β-lactamases, including metallo-β-lactamases (MBLs), which have one or two zinc ions (Zn2+) on the active site and are resistant to common inhibitors of serine β-lactamases, such as clavulanic acid, sulbactam, tazobactam, and avibactam. Therefore, the design of inhibitors against MBLs has been directed toward various compounds, with groups such as nitrogen, thiols, and metal-binding carboxylates, or compounds such as bicyclic boronates that mimic hydrolysis intermediates. Other compounds, such as dipicolinic acid and aspergillomarasmin A, have also been shown to inhibit MBLs by chelating Zn2+. In fact, recent inhibitors are based on Zn2+ chelation, which is an important factor in the mechanism of action of most MBL inhibitors. Therefore, in this review, we analyzed the current strategies for the design and mechanism of action of metal-ion-binding inhibitors that combat MDR bacteria.
24 January 2020 in Journal of Clinical Laboratory Analysis
Background: Functional variants ‐173 G > C (rs755622) and ‐794CATT 5‐8 (rs5844572) MIF gene have been associated with the risk in several types of cancer, as well as with the increase of soluble levels of MIF and TNFα. However, in previous studies contradictory and uncertain results have been presented on the implication of MIF polymorphisms with the association in cancer, specifically in breast cancer (BC). We investigated whether the variants are associated with the susceptibility to develop BC and the soluble levels of MIF and TNFα in women with BC from western Mexico. Materials and methods: A total of 152 women with BC and 182 control subjects (CS) were enrolled in this study. The determination of genotypes ‐173 G > C and ‐794 CATT 5‐8MIF polymorphisms was performed by PCR‐RFLP and PCR, respectively. In addition, the soluble levels of MIF and TNFα in both studied groups were quantified by ELISA and MILLIPLEX assay, respectively. Results: The most frequent allele found in BC was the G (74.3%) and 6 (54%) in the variants ‐173G > C and ‐794 CATT 5‐8 , respectively, without significant differences in both groups. Nevertheless, the women with BC carriers ‐173*C and ‐794CATT 7 have higher levels of MIF in comparison with CS. An increase of MIF (BC: 11.1 ng/mL vs CS: 5.2 ng/mL, P < .001) and TNFα (BC: 24.9 ng/mL vs CS: 9.9 pg/mL, P < .001) was found. Conclusion: The functional variants of MIF are not genetic susceptibility markers for BC. Nevertheless, the alleles ‐173*C and ‐794CATT 7 are associated with the increase of MIF circulating in women with BC.
19 October 2022 in International Journal of Immunopathology and Pharmacology
Nitric oxide (NO) is a molecule with multiple biological functions that is involved in various pathophysiological processes such as neurotransmission and blood vessel relaxation as well as the endocrine system, immune system, growth factors, and cancer. However, in the carcinogenesis process, it has a dual behavior; at low doses, NO regulates homeostatic functions, while at high concentrations, it promotes tissue damage or acts as an agent for immune defense against microorganisms. Thus, its participation in the carcinogenic process is controversial. Cancer is a multifactorial disease that presents complex behavior. A better understanding of the molecular mechanisms associated with the initiation, promotion, and progression of neoplastic processes is required. Some hypotheses have been proposed regarding the influence of NO in activating oncogenic pathways that trigger carcinogenic processes, because NO might regulate some signaling pathways thought to promote cancer development and more aggressive tumor growth. Additionally, NO inhibits apoptosis of tumor cells, together with the deregulation of proteins that are involved in tissue homeostasis, promoting spreading to other organs and initiating metastatic processes. This paper describes the signaling pathways that are associated with cancer, and how the concentration of NO can serve a beneficial or pathological function in the initiation and promotion of neoplastic events.
Background/Objectives: Breast cancer (BC) is a heterogeneous disease with multifactorial origins, including environmental, genetic, and immunological factors. Inflammatory cytokines, such as alpha 1 antitrypsin (α1-AT), are increased in BC and affect physiological and pathological conditions. This study aimed to evaluate the serum levels of α1-AT and perform a computational analysis of SERPINA1 in BC, as well as their association with molecular subtypes and clinical features. Methods: For the experimental analysis, we evaluated 255 women with BC and 53 healthy women (HW) in a cross-sectional study. Molecular subtypes were identified by immunohistochemistry and TNM was used for clinical staging. Soluble levels of α1-AT were quantified by ELISA. Computational analysis of SERPINA1 expression was performed using GEPIA and cBioPortal. Results: α1-AT was increased in BC women versus HW (75.8 ng/mL vs. 532.2 ng/mL). Luminal A had higher concentration (547.5 ng/mL) than Triple Negative (TN) (484.1 ng/mL), but the levels were not associated with clinical stage. The computational analysis showed that SERPINA1 is overexpressed in BC with differential expression among subtypes; its overexpression is associated with a better prognosis, longer disease-free survival, and overall survival. Conclusions: α1-AT levels are increased in women with BC women compared to HW. The Luminal A subtype shows higher soluble protein levels than the TN one. Furthermore, SERPINA1 mRNA overexpression in BC is linked to a protective effect.